A federal judge refused to throw out a court verdict upholding two Amgen patents related to its cholesterol drug, a defeat for Sanofi and Regeneron Pharmaceuticals, which make a rival drug.
Ophthotech is cutting up to 135 jobs following the failure of its two Phase III clinical trials combining the company’s Fovista and Genentech’s Lucentis to treat wet AMD.
Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.
Drug developer Akebia Therapeutics Inc. said it had signed a co-development and marketing deal worth up to $1 billion with Japan’s Otsuka Holdings Co. Ltd.
Mylan, which has come under fire for its drug pricing, will sell a generic version of its life-saving EpiPen allergy treatment at a more than 50 percent discount.
Lonza Group announced its biggest-ever acquisition with a deal to buy Capsugel, a U.S. maker of capsule products and other drug delivery systems, for $5.5 billion in cash to broaden its product range as a pharmaceuticals industry supplier.
Teleflex Inc. agreed to buy fellow medical device maker Vascular Solutions Inc. for about $1 billion.
A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.
Shares of Arrowhead Pharmaceuticals Inc. sank one day after the company said it would stop developing all drugs being tested on humans.